Identifying Serum Biomarkers for Diffuse Large B-Cell Lymphoma
Author Information
Author(s): Zhang Xing, Wang Bo, Zhang Xiao-shi, Li Zhi-ming, Guan Zhong-zhen, Jiang Wen-qi
Primary Institution: Sun Yat-sen University Cancer Center
Hypothesis
Can serum proteomic patterns be used to identify diffuse large B-cell lymphoma (DLBCL) and predict patient responses to therapy?
Conclusion
The study found specific proteomic patterns in serum that can effectively distinguish DLBCL patients from healthy individuals and predict their response to therapy.
Supporting Evidence
- Nine peaks were identified as potential biomarkers for DLBCL.
- Proteomic patterns achieved a sensitivity of 94% and specificity of 94% for detecting DLBCL.
- Four peaks were identified as biomarkers for predicting patient response to therapy.
- The study included a total of 207 serum samples.
- Patients were classified into good and poor prognosis groups based on survival.
- Decision tree analysis was used to classify DLBCL samples from controls.
- The study was approved by the Research Ethics Committee.
- SELDI-TOF-MS was used for high-throughput protein analysis.
Takeaway
Researchers looked at blood samples to find special markers that can help tell if someone has a type of cancer called DLBCL and how well they might respond to treatment.
Methodology
Serum proteomic mass spectra were analyzed using SELDI-TOF-MS from 132 DLBCL patients and 75 controls.
Potential Biases
Potential biases include variability in sample processing and the influence of confounding factors on proteomic patterns.
Limitations
The study may have variability in sample collection and processing, which could affect reproducibility.
Participant Demographics
Median age of healthy controls was 45 years, and for cancer patients, it was 52 years.
Statistical Information
P-Value
5.02E-06
Confidence Interval
95% CI = 82–99%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website